765 filings
8-K
OGEN
Oragenics Inc
19 Apr 24
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
5:48pm
8-K
OGEN
Oragenics Inc
15 Apr 24
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
8:01pm
10-K
2023 FY
OGEN
Oragenics Inc
Annual report
29 Mar 24
4:16pm
8-K
OGEN
Oragenics Inc
18 Mar 24
Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion
7:38am
SC 13G
Lind Global Fund II LP
6 Mar 24
ORAGENICS / Lind Global Fund II ownership change
4:24pm
8-K
OGEN
Oragenics Inc
1 Mar 24
Oragenics Announces Closing of Public Offering
4:05pm
424B5
OGEN
Oragenics Inc
29 Feb 24
Prospectus supplement for primary offering
4:41pm
8-K
OGEN
Oragenics Inc
28 Feb 24
Oragenics Announces Pricing of Public Offering
9:03am
8-K
OGEN
Oragenics Inc
27 Feb 24
Oragenics Announces Proposed Public Offering
5:48pm
FWP
OGEN
Oragenics Inc
27 Feb 24
Free writing prospectus
5:09pm
424B5
OGEN
Oragenics Inc
27 Feb 24
Prospectus supplement for primary offering
5:04pm
SC 13D
ODYY
Odyssey Health, Inc.
12 Feb 24
ORAGENICS / Odyssey Health ownership change
8:06pm
8-K
OGEN
Oragenics Inc
12 Feb 24
Oragenics, Inc. Announces Leadership Transition
4:45pm
8-K
OGEN
Oragenics Inc
7 Feb 24
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
8:00am
8-K
OGEN
Oragenics Inc
5 Feb 24
Other Events
8:00am
8-K
OGEN
Oragenics Inc
23 Jan 24
Oragenics Announces Termination of At-The-Market Offering Program
5:18pm
5
OGEN
Oragenics Inc
22 Jan 24
ORAGENICS / ROBERT C KOSKI ownership change
5:30pm
8-K
OGEN
Oragenics Inc
16 Jan 24
Other Events
9:10am
FWP
OGEN
Oragenics Inc
16 Jan 24
Free writing prospectus
9:08am
424B5
OGEN
Oragenics Inc
16 Jan 24
Prospectus supplement for primary offering
9:04am